{"product_id":"stratec-pestle-analysis","title":"STRATEC PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, regulatory trends, and rapid tech advances are shaping STRATEC’s market position in our concise PESTLE snapshot—insights designed to inform investment and strategy decisions; purchase the full analysis for an exhaustive, ready-to-use report that includes actionable risks, opportunities, and customizable slides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a German OEM with ~60% revenue from outside Europe (2024), STRATEC is exposed to EU‑US‑China trade tensions; tariffs on medical components could raise COGS and delay shipments for diagnostic partners, where manufacturing cost increases of even 5–10% compress OEM margins. In 2024 STRATEC reported net income €54m, so supply‑chain disruption risks could materially affect profitability; diversified manufacturing footprints across EU, Asia and North America reduce regional political risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Infrastructure Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernmental budget allocations for public health systems directly affect STRATEC’s customers; OECD reports show average health spending rose to 9.6% of GDP in 2023, boosting demand for diagnostics in well-funded markets.\u003c\/p\u003e\n\u003cp\u003eIn 2024, targeted funding for laboratory modernization in India and Brazil exceeded $1.8B combined, opening growth opportunities for automated analyzers.\u003c\/p\u003e\n\u003cp\u003eConversely, EU austerity pressures and projected 2025 capital expenditure cuts of 3–5% in hospitals may delay purchases of new diagnostic platforms, compressing near-term sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExport Control Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTRATEC’s high-tech analyzers and software fall under EU and US dual-use controls, with 2024 amendments expanding surveillance of biotech exports; recent cases show licensing backlogs increased shipments delays by 18% in life-science suppliers. Changes to export licensing for sophisticated technologies risk postponing deliveries to key markets like China and Russia, while compliance with evolving sanctions—tracked by the executive team—remains a material operational cost (2024 compliance spend ~€4.2m).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Policy Alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppolitical initiatives for pandemic preparedness and infectious disease monitoring have driven procurement spending with eu us programs allocating over in diagnostics surveillance supporting demand stratec rapid-testing platforms government consortia participation can secure multi-year contracts r funding covering up to of project costs.\u003e\n\u003cpshifts toward preventive medicine favor stratec molecular diagnostics and immunoassay segments which grew yoy in within the broader european ivd market valued at enhancing long-term revenue visibility.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic health budgets +€10bn (2024–25) supporting diagnostics\u003c\/li\u003e\n\u003cli\u003eGovt R\u0026amp;D consortia cover ~30% of project costs\u003c\/li\u003e\n\u003cli\u003eSTRATEC-relevant IVD market €15.6bn (Europe, 2024)\u003c\/li\u003e\n\u003cli\u003eSegment growth ~18% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pshifts\u003e\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReshoring and Industrial Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEuropean moves toward strategic autonomy in medtech—backed by the EU’s 2024 Chips and Health initiatives and Germany’s 2025 industrial subsidies—boost incentives for localized R\u0026amp;D and production; EU announced €10bn+ for health sovereignty 2024–2027, increasing grant opportunities for STRATEC.\u003c\/p\u003e\n\u003cp\u003eSTRATEC stands to gain from German tax credits and production subsidies aiming to retain IP and high-value manufacturing, supporting its German-centric engineering and potential margin stability amid reshoring trends.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEU health sovereignty funding: €10bn+ (2024–2027)\u003c\/li\u003e\n\u003cli\u003eGermany industrial subsidy programs expanded in 2025\u003c\/li\u003e\n\u003cli\u003eBenefit: increased grants\/tax credits for onshore R\u0026amp;D and manufacturing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics raise costs and delays but EU health funding fuels onshoring and demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risks include EU‑US‑China trade tensions raising COGS and delays (5–10% margin impact), export control tightening increasing shipment lead times (~18% in 2024) and compliance costs (~€4.2m); government health spending (+€10bn in 2024–25) and EU health sovereignty funds (€10bn+ 2024–27) support demand and grants for onshoring.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet income\u003c\/td\u003e\n\u003ctd\u003e€54m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e€4.2m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth spending support\u003c\/td\u003e\n\u003ctd\u003e+€10bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU health funds\u003c\/td\u003e\n\u003ctd\u003e€10bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect STRATEC across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends, sector-specific subpoints, and forward-looking insights to aid executives, consultants, and investors in spotting risks, opportunities, and strategy-ready recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise, visually segmented PESTLE summary of STRATEC that’s easy to drop into presentations or share across teams, helping stakeholders quickly align on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Outsourcing Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpmacroeconomic pressure is driving large diagnostics firms to outsource instrument development oems like stratec cutting r exposure global in-vitro market saw cagr and budgets tightened in this trend yields steady long-term service contracts fees reported ebit margin resilience with\u003e60% recurring revenue. The pivot from in-house production to partnership models remains a key economic tailwind, supporting revenue predictability amid market volatility.\n\u003c\/pmacroeconomic\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFluctuations in global interest rates affect STRATEC’s cost of capital for expansion and the financing ability of its diagnostic-lab customers; ECB rates rose to 4.0% in 2024, raising borrowing costs across Europe. Higher rates can slow replacement cycles for large-scale lab equipment, with European medical-capex growth falling to 1.2% in 2024. STRATEC’s net cash position (€83m at FY2024) and low net debt\/EBITDA (~0.2x) help it withstand tighter credit versus smaller peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith roughly 60% of STRATEC’s FY2024 revenue invoiced in USD while major costs remain in EUR, the firm faces material transaction and translation risk as EUR\/USD swung ~8% in 2024–2025; hedging (forwards, options) is essential to protect EBITDA margins (gross margin pressure of ~150–200 bps per 5% FX move). Economic instability in key markets could reduce service contract renewals and compress margins on international maintenance agreements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cprising costs for raw materials electronic components and specialized labor prices up about yoy in medical device suppliers squeeze stratec margins if not passed to oems long-term contracts with price-adjustment clauses mitigate but face a month lag between cost spikes revenue relief.\u003e\u003cpefficient supply-chain management and lean manufacturing helped peers cut cogs by up to in a critical offset for stratec protect ebitda margins near\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInput inflation 8–12% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eContract lag 3–9 months\u003c\/li\u003e\n\u003cli\u003ePotential COGS savings via lean ops ~4%\u003c\/li\u003e\n\u003cli\u003eTarget EBITDA range 15–17%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pefficient\u003e\u003c\/prising\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising GDP in Asia and Latin America expanded the middle class to ~3.5 billion globally by 2024, boosting demand for modern diagnostics and increasing annual test volumes—e.g., India’s IVD market hit ~USD 3.2bn in 2024 (CAGR ~10% 2019–24).\u003c\/p\u003e\n\u003cp\u003eSTRATEC’s scalable, high-throughput analyzers address this demand; scalable partnerships and localized manufacturing can drive revenue growth beyond 8–12% CAGR in emerging markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMiddle-class expansion → more diagnostics\u003c\/li\u003e\n\u003cli\u003eIndia IVD ~USD 3.2bn (2024), Asia-Pacific leading growth\u003c\/li\u003e\n\u003cli\u003eHigh-throughput analyzers meet volume needs\u003c\/li\u003e\n\u003cli\u003eScalability drives +8–12% potential EM revenue CAGR\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSTRATEC: \u0026gt;60% recurring revenue, resilient margins amid 5.6% IVD CAGR and FX\/input risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacro trend: OEM outsourcing drives recurring dev\/service revenue; IVD market CAGR 5.6% (2020–25); STRATEC \u0026gt;60% recurring rev, EBIT margin resilient (FY2024). Rates\/credit: ECB 4.0% (2024) – capex growth 1.2%; net cash €83m, net debt\/EBITDA ~0.2x. FX\/input risks: EUR\/USD ±8% (2024–25) and input inflation 8–12% (2024); contract lag 3–9m; EM growth (India IVD ~USD 3.2bn 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIVD CAGR (2020–25)\u003c\/td\u003e\n\u003ctd\u003e5.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring rev\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eECB rate (2024)\u003c\/td\u003e\n\u003ctd\u003e4.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash (FY2024)\u003c\/td\u003e\n\u003ctd\u003e€83m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~0.2x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput inflation (2024)\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEUR\/USD swing (2024–25)\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia IVD (2024)\u003c\/td\u003e\n\u003ctd\u003e~USD 3.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSTRATEC PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact STRATEC PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751277113721,"sku":"stratec-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/stratec-pestle-analysis.png?v=1772229642","url":"https:\/\/growthsharematrix.com\/products\/stratec-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}